[1] | Kjeldsen, S.E., Hypertension and cardiovascular risk: General aspects. Pharmacol Res, 2018. 129: p. 95-99. |
|
[2] | Dad, T. and D.E. Weiner, Stroke and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management Across Kidney Disease Stages. Semin Nephrol, 2015. 35(4): p. 311-22. |
|
[3] | Lawes, C.M., et al., Blood pressure and stroke: an overview of published reviews. Stroke, 2004. 35(4): p. 1024. |
|
[4] | System, U.S.R.D., Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, in USRDS Annual Data Report. 2009, National Institute of Diabetes and Digestive and Kidney Disease. |
|
[5] | Murray, C.J., et al., The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA, 2013. 310(6): p. 591-608. |
|
[6] | Mills, K.T., et al., Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation, 2016. 134(6): p. 441-50. |
|
[7] | Egan, B.M., et al., Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation, 2014. 130(19): p. 1692-9. |
|
[8] | Fryar, C.D., et al., Hypertension Prevalence and Control Among Adults: United States, 2015-2016. NCHS Data Brief, 2017(289): p. 1-8. |
|
[9] | Egan, B.M., Y. Zhao, and R.N. Axon, US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA, 2010. 303(20): p. 2043-50. |
|
[10] | Heidenreich, P.A., et al., Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation, 2011. 123(8): p. 933-44. |
|
[11] | Kirkland, E.B., et al., Trends in Healthcare Expenditures Among US Adults With Hypertension: National Estimates, 2003-2014. J Am Heart Assoc, 2018. 7(11). |
|
[12] | Carnethon, M.R., et al., Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association. Circulation, 2017. 136(21): p. e393-e423. |
|
[13] | Ferdinand, K.C. and R.R. Townsend, Hypertension in the US Black population: risk factors, complications, and potential impact of central aortic pressure on effective treatment. Cardiovasc Drugs Ther, 2012. 26(2): p. 157-65. |
|
[14] | Muntner, P., et al., Trends in blood pressure among children and adolescents. JAMA, 2004. 291(17): p. 2107-13. |
|
[15] | Kalinowski, L., I.T. Dobrucki, and T. Malinski, Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation, 2004. 109(21): p. 2511-7. |
|
[16] | Hozawa, A., et al., Absolute and attributable risks of cardiovascular disease incidence in relation to optimal and borderline risk factors: comparison of African American with white subjects--Atherosclerosis Risk in Communities Study. Archives of internal medicine, 2007. 167(6): p. 573-9. |
|
[17] | Benjamin, E.J., et al., Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation, 2019. 139(10): p. e56-e528. |
|
[18] | Go, A.S., et al., Heart disease and stroke statistics--2014 update: a report from the american heart association. Circulation, 2014. 129(3): p. e28-e292. |
|
[19] | Egan, B.M., et al., Hypertension in the United States 1999–2012: Progress Toward Healthy People 2020 Goals. Circulation, 2014. 130(19): p. 1692-9. |
|
[20] | Thorpe, R.J., et al., Economic Burden of Men's Health Disparities in the United States. International Journal of Men's Health, 2013. 12(3). |
|
[21] | Ferdinand, K.C. and A. Armani, Cardiovascular Disease in Racial and Ethnic Minorities. 2010: Humana; Springer Science & Buisness Media. |
|
[22] | Ferdinand, K.C. and A.M. Armani, The management of hypertension in African Americans. Critical pathways in cardiology, 2007. 6(2): p. 67-71. |
|
[23] | Diaz, K.M., et al., Prevalence, Determinants, and Clinical Significance of Masked Hypertension in a Population-Based Sample of African Americans: The Jackson Heart Study. Am J Hypertens, 2015. 28(7): p. 900-8. |
|
[24] | Patel, P.D., J.L. Velazquez, and R.R. Arora, Endothelial dysfunction in African-Americans. Int J Cardiol, 2009. 132(2): p. 157-72. |
|
[25] | Veerabhadrappa, P., et al., Endothelial-dependent flow-mediated dilation in African Americans with masked-hypertension. Am J Hypertens, 2011. 24(10): p. 1102-7. |
|
[26] | Perticone, F., et al., Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation, 2001. 104(2): p. 191-6. |
|
[27] | Cardillo, C. and J.A. Panza, Impaired endothelial regulation of vascular tone in patients with systemic arterial hypertension. Vasc Med, 1998. 3(2): p. 138-44. |
|
[28] | Taddei, S., et al., Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation, 1996. 94(6): p. 1298-303. |
|
[29] | Campia, U., et al., Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. J Am Coll Cardiol, 2002. 40(4): p. 754-60. |
|
[30] | Perregaux, D., et al., Brachial vascular reactivity in blacks. Hypertension, 2000. 36(5): p. 866-71. |
|
[31] | Cook, M.D., Endothelial Cell Function and Hypertension: Interactions Among Inflammation, Immune Function, and Exercise, in Effects of Exercise on Hypertension: From Cells to Physiological Systems, L.S. Pescatello, Editor. 2015, Humana Press: Springer: New York. p. 301-323. |
|
[32] | Babbitt, D.M., et al., Endothelial activation microparticles and inflammation status improve with exercise training in african americans. International journal of hypertension, 2013. 2013: p. 538017. |
|
[33] | Brown, M.D., et al., Racial differences in tumor necrosis factor-alpha-induced endothelial microparticles and interleukin-6 production. Vascular health and risk management, 2011. 7: p. 541-50. |
|
[34] | Diaz, K.M., et al., Visit-to-visit and 24-h blood pressure variability: association with endothelial and smooth muscle function in African Americans. J Hum Hypertens, 2013. 27(11): p. 671-7. |
|
[35] | Feairheller, D.L., et al., Effects of moderate aerobic exercise training on vascular health and blood pressure in African Americans. J Clin Hypertens (Greenwich), 2014. 16(7): p. 504-10. |
|
[36] | Brown, M.D. and D.L. Feairheller, Are there race-dependent endothelial cell responses to exercise? Exerc Sport Sci Rev, 2013. 41(1): p. 44-54. |
|
[37] | Brown, M.D., et al., Racial differences in tumor necrosis factor-alpha-induced endothelial microparticles and interleukin-6 production. Vasc Health Risk Manag, 2011. 7: p. 541-50. |
|
[38] | Feairheller, D.L., et al., Racial differences in oxidative stress and inflammation: in vitro and in vivo. Clin Transl Sci, 2011. 4(1): p. 32-7. |
|
[39] | Lovren, F. and S. Verma, Evolving role of microparticles in the pathophysiology of endothelial dysfunction. Clin Chem, 2013. 59(8): p. 1166-74. |
|
[40] | Spieker, L.E., et al., Working under pressure: the vascular endothelium in arterial hypertension. J Hum Hypertens, 2000. 14(10-11): p. 617-30. |
|
[41] | Ekholm, M., et al., Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension. J Cardiovasc Pharmacol, 2018. 71(4): p. 240-247. |
|
[42] | Lund, L.H., ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives. Evid Based Med, 2016. 21(1): p. 33-4. |
|
[43] | Grimm, H., et al., The Effects of Exercise, Aspirin, and Celecoxib in an Atherogenic Environment. Med Sci Sports Exerc, 2018. 50(10): p. 2033-2039. |
|
[44] | Cheng, Y., et al., Role of prostacyclin in the cardiovascular response to thromboxane A2. Science, 2002. 296(5567): p. 539-41. |
|
[45] | Cipollone, F., G. Cicolini, and M. Bucci, Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther, 2008. 118(2): p. 161-80. |
|
[46] | Collado, M.C., et al., Gut microbiota: a source of novel tools to reduce the risk of human disease? Pediatr Res, 2015. 77(1-2): p. 182-8. |
|
[47] | Sekirov, I., et al., Gut microbiota in health and disease. Physiol Rev, 2010. 90(3): p. 859-904. |
|
[48] | Guo, Z., et al., Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials. Nutr Metab Cardiovasc Dis, 2011. 21(11): p. 844-50. |
|
[49] | Tabuchi, M., et al., Antidiabetic effect of Lactobacillus GG in streptozotocin-induced diabetic rats. Biosci Biotechnol Biochem, 2003. 67(6): p. 1421-4. |
|
[50] | Cole-Jeffrey, C.T., et al., ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy. J Cardiovasc Pharmacol, 2015. |
|
[51] | Khalesi, S., et al., Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension, 2014. 64(4): p. 897-903. |
|
[52] | Gomez-Guzman, M., et al., Antihypertensive effects of probiotics Lactobacillus strains in spontaneously hypertensive rats. Mol Nutr Food Res, 2015. |
|
[53] | Yang, T., et al., Gut dysbiosis is linked to hypertension. Hypertension, 2015. 65(6): p. 1331-40. |
|
[54] | Yan, Q., et al., Alterations of the Gut Microbiome in Hypertension. Front Cell Infect Microbiol, 2017. 7: p. 381. |
|
[55] | Hester, C.M., et al., Fecal microbes, short chain fatty acids, and colorectal cancer across racial/ethnic groups. World J Gastroenterol, 2015. 21(9): p. 2759-69. |
|
[56] | Ciubotaru, I., et al., Significant differences in fecal microbiota are associated with various stages of glucose tolerance in African American male veterans. Transl Res, 2015. 166(5): p. 401-11. |
|
[57] | Goodrich, J.K., et al., Human genetics shape the gut microbiome. Cell, 2014. 159(4): p. 789-99. |
|
[58] | Ou, J., et al., Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans. Am J Clin Nutr, 2013. 98(1): p. 111-20. |
|
[59] | O'Keefe, S.J., Diet, microorganisms and their metabolites, and colon cancer. Nat Rev Gastroenterol Hepatol, 2016. 13(12): p. 691-706. |
|
[60] | Bailey, M.T., Psychological Stress, Immunity, and the Effects on Indigenous Microflora. Adv Exp Med Biol, 2016. 874: p. 225-46. |
|
[61] | Serino, M., et al., Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences. Curr Cardiol Rep, 2014. 16(11): p. 540. |
|
[62] | Desai, M.S., et al., A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. Cell, 2016. 167(5): p. 1339-1353 e21. |
|
[63] | Santisteban, M.M., et al., Hypertension-Linked Pathophysiological Alterations in the Gut. Circ Res, 2016. |
|
[64] | Li, J., et al., Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome, 2017. 5(1): p. 14. |
|
[65] | Podschun, R. and U. Ullmann, Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev, 1998. 11(4): p. 589-603. |
|
[66] | Ley, R.E., Gut microbiota in 2015: Prevotella in the gut: choose carefully. Nat Rev Gastroenterol Hepatol, 2016. 13(2): p. 69-70. |
|
[67] | Kumar, S., et al., Novel aromatic ester from Piper longum and its analogues inhibit expression of cell adhesion molecules on endothelial cells. Biochemistry, 2005. 44(48): p. 15944-52. |
|
[68] | Chamkha, M., J.L. Garcia, and M. Labat, Metabolism of cinnamic acids by some Clostridiales and emendation of the descriptions of Clostridium aerotolerans, Clostridium celerecrescens and Clostridium xylanolyticum. Int J Syst Evol Microbiol, 2001. 51(Pt 6): p. 2105-11. |
|
[69] | Morrison, D.J. and T. Preston, Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes, 2016. 7(3): p. 189-200. |
|
[70] | Pevsner-Fischer, M., et al., The gut microbiome and hypertension. Curr Opin Nephrol Hypertens, 2017. 26(1): p. 1-8. |
|
[71] | Wong, J.M., et al., Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol, 2006. 40(3): p. 235-43. |
|
[72] | O'Keefe, S.J., et al., Why do African Americans get more colon cancer than Native Africans? J Nutr, 2007. 137(1 Suppl): p. 175S-182S. |
|
[73] | Pluznick, J., A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes, 2014. 5(2): p. 202-7. |
|
[74] | Zapolska-Downar, D., et al., Butyrate inhibits cytokine-induced VCAM-1 and ICAM-1 expression in cultured endothelial cells: the role of NF-kappaB and PPARalpha. J Nutr Biochem, 2004. 15(4): p. 220-8. |
|
[75] | van der Beek, C.M., et al., Hepatic Uptake of Rectally Administered Butyrate Prevents an Increase in Systemic Butyrate Concentrations in Humans. J Nutr, 2015. 145(9): p. 2019-24. |
|
[76] | Wilck, N., et al., Salt-responsive gut commensal modulates TH17 axis and disease. Nature, 2017. 551(7682): p. 585-589. |
|
[77] | LeBlanc, J.G., et al., Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. Microb Cell Fact, 2017. 16(1): p. 79. |
|
[78] | Cook, M.D., et al., Exercise and gut immune function: Evidence of alterations in colon immune cell homeostasis and microbiome characteristics with exercise training. Immunol Cell Biol, 2015. |
|
[79] | Allen, J.M., et al., Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans. Med Sci Sports Exerc, 2017. |
|
[80] | Mailing, L.J., et al., Exercise and the Gut Microbiome: A Review of the Evidence, Potential Mechanisms, and Implications for Human Health. Exerc Sport Sci Rev, 2019. 47(2): p. 75-85. |
|
[81] | Brown, M.D. and D.L. Feairheller, Are there race-dependent endothelial cell responses to exercise? Exercise and sport sciences reviews, 2013. 41(1): p. 44-54. |
|
[82] | Gleeson, M., et al., The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nature reviews. Immunology, 2011. 11(9): p. 607-15. |
|
[83] | Wilson, I.D. and J.K. Nicholson, Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res, 2017. 179: p. 204-222. |
|